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Abstract
The N-Myc oncoprotein is a critical factor in neuroblastoma tumorigenesis which requires additional mechanisms
converting a low-level to a high-level N-Myc expression. N-Myc protein is stabilized when phosphorylated at Serine 62 by
phosphorylated ERK protein. Here we describe a novel positive feedback loop whereby N-Myc directly induced the
transcription of the class III histone deacetylase SIRT1, which in turn increased N-Myc protein stability. SIRT1 binds to Myc
Box I domain of N-Myc protein to form a novel transcriptional repressor complex at gene promoter of mitogen-activated
protein kinase phosphatase 3 (MKP3), leading to transcriptional repression of MKP3, ERK protein phosphorylation, N-Myc
protein phosphorylation at Serine 62, and N-Myc protein stabilization. Importantly, SIRT1 was up-regulated, MKP3 down-
regulated, in pre-cancerous cells, and preventative treatment with the SIRT1 inhibitor Cambinol reduced tumorigenesis in
TH-MYCN transgenic mice. Our data demonstrate the important roles of SIRT1 in N-Myc oncogenesis and SIRT1 inhibitors in
the prevention and therapy of N-Myc–induced neuroblastoma.
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Introduction
Neuroblastoma, which originates from precursor neuroblast
cells, is the most common solid tumor in early childhood. MYCN
oncogene amplification and consequent N-Myc mRNA and
protein over-expression, are seen as a clonal feature in a quarter
of tumors, and correlate with poorer prognosis in patients with
neuroblastoma [1,2].
Myc oncoproteins, including N-Myc and c-Myc, induce
malignant transformation by binding to cognate DNA sequences
and modulating gene transcription, leading to cell proliferation
[3]. Stabilization and degradation of Myc oncoproteins are
controlled by ordered phosphorylation at two specific sites: Serine
62 (S62) and Threonine 58 (T58). While T58 phosphorylation
promotes Myc protein ubiquitylation and degradation through the
26S proteasome-mediated proteolysis, S62 phosphorylation stabi-
lizes Myc proteins [4–6]. One of the key factors which promote
Myc protein phosphorylation at S62 is extracellular signal-
regulated protein kinase (ERK) [4].
Recruitment of histone deacetylase (HDAC) proteins to gene
promoters induces histone hypo-acetylation and transcriptional
repression, particularly of tumor suppressor genes [7]. Gene
expression and deacetylase activity of the class III HDAC SIRT1
are often altered in human cancer tissues (reviewed in [8]). SIRT1
is up-regulated in poorly differentiated adenocarcinomas, com-
pared with normal counterparts, in three transgenic mouse models
of prostate cancer and in human prostate tumor tissues [9]. SIRT1
is also over-expressed in human gastric cancer tissues, and SIRT1
over-expression correlates with advanced disease stage, tumor
metastasis and poor patient prognosis [10]. Paradoxically, SIRT1
expression is reduced in human colon cancer tissues in general
[11], but significantly over-expressed in human colon cancer
tissues associated with microsatellite instability and CpG island
methylator phenotype [12].
SIRT1 induces histone deacetylation and methylation [13,14],
promoter CpG island methylation [15], transcriptional repression
of tumor suppressor genes [16], and deacetylation of tumor
suppressor proteins [17,18]. SIRT1 may therefore play a critical
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and/or promoting cell growth. On the other hand, by deacetylat-
ing catenin and survivin, SIRT1 can block cell proliferation and
promote apoptosis [19,20].
In the current study, we have identified two Myc-responsive
element E-Boxes at the SIRT1 gene core promoter, and shown
that N-Myc up-regulated SIRT1 gene transcription. In a positive
feedback loop, SIRT1 binds to Myc Box I domain of N-Myc
protein to form a novel transcriptional repressor complex at the
gene promoter of mitogen-activated protein kinase phosphatase 3
(MKP3), leading to transcriptional repression of MKP3, ERK
protein phosphorylation, N-Myc protein phosphorylation at
Serine 62 and N-Myc protein stabilization. These mechanisms
contributed directly to the initiation and progression of N-Myc-
driven oncogenesis in a murine model of neuroblastoma.
Results
Transcriptional up-regulation of SIRT1 by N-Myc
promotes neuroblastoma cell proliferation
By screening human gene promoter regions with GenoMatix
software, we found two Myc-responsive element E-boxes 2136 bp
and 257 bp upstream of the SIRT1 transcription start site. We
therefore examined possible modulation of SIRT1 expression by
N-Myc. We previously demonstrated that transfection of MYCN-
amplified BE(2)-C human neuroblastoma cells with N-Myc siRNA
No.1 (N-Myc siRNA-1) or No.2 (N-Myc siRNA-2) significantly
reduced N-Myc mRNA and protein expression [21]. As shown in
Figure 1A, N-Myc siRNA-1 and N-Myc siRNA-2 also significantly
reduced N-Myc mRNA and protein expression in MYCN-
amplified LAN-1 human neuroblastoma cells, and SIRT1
siRNA-1 and SIRT1 siRNA-2 knocked down SIRT1 mRNA
and protein expression in both BE(2)-C and LAN-1 cells.
Importantly, N-Myc siRNA-1 and N-Myc siRNA-2 significantly
reduced SIRT1 mRNA and protein expression in the two
neuroblastoma cell lines (Figure 1A). We have previously shown
that N-Myc expression was increased by approximately 100% in
neuroblastoma SHEP TET-OFF cells, which were stably
transfected with a tetracycline withdrawal-inducible N-Myc-
expression construct, after tetracycline withdrawal from cell
culture medium [22]. As shown in Figure 1B, when N-Myc is
over-expressed in SHEP TET-OFF cells after tetracycline
withdrawal and in normal mouse bone marrow-derived B cells
after transfection with an N-Myc-expression construct (Figure S1),
SIRT1 mRNA expression was up-regulated. Chromatin immu-
noprecipitation (ChIP) assays showed that anti-N-Myc antibody
efficiently immunoprecipitated the region of SIRT1 gene core
promoter carrying the E-boxes (Figure 1C and 1D). These data
suggest that N-Myc up-regulates SIRT1 gene expression by
directly binding to the E-Boxes at SIRT1 gene core promoter.
We next examined whether up-regulation of SIRT1 contributed
to an N-Myc-induced cancer phenotype. Alamar blue assays
revealed that N-Myc siRNA-1, N-Myc siRNA-2, SIRT1 siRNA-1
or SIRT1 siRNA-2 reduced cell numbers by approximately 50%
in p53-mutant BE(2)-C and LAN-1 cells in 3 days (Figure 1E).
Similarly, repression of SIRT1 with Cambinol, a small molecule
SIRT1 inhibitor [23], induced a dose-dependent growth inhibition
(Figure 1F). TUNEL assays showed that N-Myc siRNAs, SIRT1
siRNAs and Cambinol did not significantly induce cell death in the
p53-mutant neuroblastoma cells (data not shown). Moreover,
Alamar blue assays demonstrated that repression of SIRT1 with
the small molecule inhibitor Tenovin-6 [24] also induced a dose-
dependent growth inhibition (Figure 1G). These data suggest that
transcriptional up-regulation of SIRT1 contributes to N-Myc-
induced cell proliferation.
SIRT1 stabilizes N-Myc protein
Surprisingly, our immunoblot analyses showed that SIRT1
siRNAs reduced N-Myc protein expression. As shown in
Figure 2A, both SIRT1 siRNA-1 and SIRT1 siRNA-2 reduced
the N-Myc protein expression level in BE(2)-C and LAN-1 cells.
Real-time RT-PCR analysis showed that the SIRT1 siRNAs did
not reduce N-Myc mRNA expression (Figure S2A). Moreover,
treatment with the SIRT1 inhibitors, Cambinol [23] or Tenovin-6
[24], consistently reduced the expression of N-Myc protein
(Figure 2B), but not N-Myc mRNA (Figure S2B).
Because N-Myc protein is degraded through proteasome-
mediated proteolysis, we treated BE(2)-C cells with the proteasome
inhibitor MG-132 after siRNA transfection. Immunoblot analyses
showed that MG-132 dramatically up-regulated the expression of
N-Myc protein, but not SIRT1 protein, in cells transfected with
scrambled control siRNA (Figure 2C, upper panel). While MG-
132 did not increase N-Myc protein expression in cells transfected
with N-Myc siRNAs, which ablated N-Myc mRNA, MG-132
significantly up-regulated N-Myc protein expression in cells
transfected with SIRT1 siRNA-1 or SIRT1 siRNA-2 for 48 hours
(Figure 2C, middle and bottom panels). We next treated BE(2)-C
cells with 50 mM cycloheximide (CHX) at different time points
after transfection with control siRNA or SIRT1 siRNA-1 for only
30 hours, when the effect of SIRT1 siRNA-1 on N-Myc protein
expression was minimal. Immunoblot analysis showed that N-Myc
protein half-life was reduced from 48 minutes in cells transfected
with control siRNA to 20 minutes in cells transfected with SIRT1
siRNA-1 (Figure 2D). Taken together, these data suggest that
SIRT1 reduces proteasome-mediated N-Myc protein degradation
and therefore stabilizes N-Myc protein.
SIRT1 stabilizes N-Myc protein by promoting ERK protein
phosphorylation and N-Myc protein phosphorylation at
S62
When phosphorylated at T58, Myc oncoproteins are degraded
through proteasome-mediated proteolysis. By contrast, when
phosphorylated at S62, Myc protein degradation is blocked
[4,5]. We therefore examined whether SIRT1 increased N-Myc
protein stability by modulating N-Myc protein phosphorylation.
As shown in Figure 3A, transfection of BE(2)-C cells with SIRT1
siRNA-1 or SIRT1 siRNA-2 reduced T58-phosphorylated N-Myc
protein and total N-Myc protein to a similar extent. However, a
Author Summary
The class III histone deacetylase SIRT1 is repressed by
tumor suppressor genes and exerts divergent effects on
tumorigenesis depending on its down-stream targets.
Small molecule SIRT1 inhibitors have shown promising
anti-cancer effects both in vitro and in vivo. Here we
identified SIRT1 as a gene directly up-regulated by N-Myc
and identified SIRT1-mediated transcriptional repression as
a novel mechanism responsible for maintaining N-Myc
oncoprotein stability. Moreover, SIRT1 contributed to N-
Myc–induced cell proliferation, and preventative treatment
with the SIRT1 inhibitor Cambinol reduced tumorigenesis
in N-Myc transgenic mice. Our data identify SIRT1 as an
important co-factor for N-Myc oncogenesis and provide
important evidence for the potential application of SIRT1
inhibitors in the prevention and therapy of N-Myc–induced
neuroblastoma.
Histone Deacetylase SIRT1 Promotes Neuroblastoma
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observed after SIRT1 knock-down, suggesting that SIRT1
stabilized N-Myc protein by promoting its phosphorylation at S62.
N-Myc protein phosphorylation at S62 is directly enhanced by
phosphorylated ERK [4], and indirectly decreased by glycogen
synthase kinase 3 (GSK3) which increases N-Myc protein
phosphorylation at T58 and consequent proteasome-mediated
degradation [25]. We therefore examined whether SIRT1
modulated ERK protein phosphorylation and GSK3 protein
expression. As shown in Figure 3B, SIRT1 siRNA-1 and SIRT1
siRNA-2 had no significant effect on GSK3 protein expression,
but consistently decreased ERK protein phosphorylation. These
data suggest that SIRT1 stabilizes N-Myc protein by up-regulating
ERK protein phosphorylation, which in turn phosphorylates N-
Myc protein at S62 and blocks its degradation.
Because SIRT1 siRNA-2 and N-Myc siRNA-2 did not show
appreciable differences from SIRT1 siRNA-1 and N-Myc siRNA-
1 respectively in all of the above-mentioned experiments, we
decided to use SIRT1 siRNA-1 and N-Myc siRNA-1 only in all of
the following experiments, and referred them as SIRT1 siRNA
and N-Myc siRNA respectively.
Repression of MKP3 gene expression is required for
SIRT1-induced N-Myc protein stabilization and for
SIRT1-induced cell proliferation
To identify transcriptional target genes responsible for SIRT1-
induced ERK protein phosphorylation, we performed differential
gene expression studies with Affymetrix Gene Array in BE(2)-C
cells 30 hours after transfection with scrambled control or SIRT1
siRNA. As shown in Dataset S1 and Dataset S2, the gene second
most significantly reactivated by SIRT1 siRNA was mitogen-
activated protein kinase phosphatase 3 (MKP3)/dual specificity
phosphatase 6 (DUSP6)/Pyst1, which selectively de-phosphory-
lates and inactivates ERK [26,27]. Importantly, MKP3 was also
up-regulated by N-Myc siRNA by approximately 3 fold in BE(2)-C
cells 30 hours after siRNA transfection in our previous Affymetrix
Gene Array data [21].
To validate the gene array data, we performed real-time RT-
PCR and immunoblot analyses of MKP3 expression. As shown in
Figure 4A and 4D, the expression of MKP3 mRNA and protein
was up-regulated by SIRT1 siRNA and N-Myc siRNA in BE(2)-
C and LAN-1 cells. Consistently, transfection of primary mouse
bone marrow-derived B cells with an N-Myc-expression construct
reduced MKP3 expression by approximately 50% (Figure 4B),
and repression of SIRT1 with Cambinol or Tenovin-6 reactivat-
ed MKP3 expression in both BE(2)-C and LAN-1 cells (Figure 4C
and 4D). These data demonstrate that MKP3 is transcriptionally
repressed by SIRT1 and N-Myc, and that SIRT1 inhibitors can
be applied to reverse the effect. Moreover, RT-PCR analyses
demonstrated that both SIRT1 siRNA and the SIRT1 inhibitor
Cambinol up-regulated the expression of the other SIRT1 target
genes including early growth response 1 (EGR1), Kv channel
interacting protein 4 (KCNIP4) and phospholipase C beta 1
(PLCB1), which were randomly selected from the Affymetrix
Gene Array data (Dataset S1), in BE(2)-C and LAN-1 cells
(Figure S4).
As MKP3 is well-known to selectively de-phosphorylate the
ERK protein [26,27], we examined whether blocking MKP3 gene
reactivation could reverse the effects of SIRT1 siRNA on ERK
and N-Myc protein de-phosphorylation. As shown in Figure 4E,
MKP3 siRNA alone did not have a significant effect on ERK and
N-Myc protein phosphorylation, possibly due to a very low basal
level of MKP3 expression. While SIRT1 siRNA alone dramati-
cally reduced ERK protein phosphorylation and N-Myc protein
phosphorylation at S62, co-transfection with MKP3 siRNA
restored phosphorylated ERK, S62-phosphorylated N-Myc and
total N-Myc protein levels. These data suggest that SIRT1-
modulated transcriptional repression of MKP3 is essential for
ERK protein phosphorylation, N-Myc protein phosphorylation at
S62 and consequent N-Myc protein stabilization.
We next examined whether transcriptional activation of MKP3
contributed to cell growth inhibition induced by SIRT1 siRNA
and the SIRT1 inhibitor Cambinol. While repression of MKP3
gene expression alone did not have an effect on cell proliferation,
co-transfection of MKP3 siRNA significantly blocked the growth
inhibition caused by SIRT1 siRNA and Cambinol in BE(2)-C
(Figure 4F) and LAN-1 (Figure S3) cells. These data indicate that
transcriptional repression of MKP3 contributes to SIRT1-induced
neuroblastoma cell proliferation.
SIRT1 and N-Myc repress MKP3 gene transcription by
forming a transcriptional repressor complex at
Sp1-binding sites of MKP3 gene promoter
SIRT1 is known to repress gene transcription by binding to
Sp1-binding sites at target gene promoters [28]. We have
previously shown that N-Myc represses the transcription of the
tissue transglutaminase gene by recruiting HDAC1 protein to
tissue transglutaminase gene promoter [22]. As both N-Myc and
SIRT1 suppressed MKP3 gene expression, we tested the
hypothesis that N-Myc and SIRT1 repressed MKP3 gene
transcription by forming a transcriptional repressor complex at
Sp1-binding sites of MKP3 gene promoter. Bio-informatics
analysis of the MKP3 gene promoter (22000/+0 from transcrip-
tion start site) identified one region proximal to the transcription
start site enriched for Sp1-binding sites (Figure 5A). Dual cross-
linking ChIP assay showed that antibodies against N-Myc, SIRT1
and Sp1 all efficiently immunoprecipitated the region of MKP3
gene promoter carrying Sp1-binding sites (Figure 5B). By
contrast, an antibody against Miz1, a protein that is often
involved in Myc-driven transcriptional repression [29], immuno-
precipitated the gene promoter region of p21 (positive control),
but not the gene promoter region of MKP3 (Figure S5A). To
Figure 1. Transcriptional up-regulation of SIRT1 promotes neuroblastoma cell proliferation. (A) BE(2)-C and LAN-1 neuroblastoma cells
were transfected with scrambled control (Cont) siRNA, N-Myc siRNA-1, N-Myc siRNA-2, SIRT1 siRNA-1 or SIRT1 siRNA-2 for 48 hours, followed by RNA
and protein extraction, real-time RT-PCR and immunoblot analyses of N-Myc and SIRT1 mRNA and protein expression. (B) Tetracycline (TET) was
withdrawn from SHEP TET-OFF cell culture medium to induce N-Myc gene expression, and B-cells were purified from normal mouse bone marrow
and transfected with a construct over-expressing full-length N-Myc cDNA or empty vector (EV). SIRT1 gene expression in the cells was analysed by
real-time RT-PCR. (C) Schematic representation of the human SIRT1 gene promoter. (D) ChIP assay was performed with control or anti-N-Myc
antibody (Ab) and primers targeting amplicon B in BE(2)-C cells. Fold enrichment of SIRT1 gene promoter by the antibodies was calculated by
dividing the PCR product from antibody-immunoprecipitated samples by the PCR product from input. (E, F, G) BE(2)-C and LAN-1 cells were
transfected with scrambled control siRNA, N-Myc siRNA-1, N-Myc siRNA-2, SIRT1 siRNA-1 or SIRT1 siRNA-2 (E), or treated with vehicle control,
Cambinol (F) or Tenovin-6 (G). Seventy-two hours later, relative cell numbers were examined by the Alamar blue assay, and expressed as percentage
change in cell number. Error bars represented standard error. * indicated P,0.05, ** P,0.01 and *** P,0.001.
doi:10.1371/journal.pgen.1002135.g001
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mediated by N-Myc, we transfected a Luciferase reporter
construct carrying MKP3 gene promoter into TET21/N cells,
a human neuroblastoma cell line carrying a MYCN transgene
under the control of a TET-OFF promoter. Luciferase assays
showed that repression of N-Myc expression significantly
activated the MKP3 gene promoter (Figure 5C). To demonstrate
that N-Myc and SIRT1 form a protein complex, we transfected
human embryonic HEK 293 cells with an empty vector, a SIRT1
expressing construct [30] and/or an N-Myc expressing construct,
extracted nuclear protein and performed protein co-immunopre-
cipitation (IP) assays (Figure 5D). Results showed that anti-SIRT1
antibody could efficiently co-immunoprecipitate N-Myc protein,
and anti-N-Myc antibody could efficiently co-immunoprecipitate
SIRT1 protein. By contrast, anti-SIRT1 antibody did not co-
immunoprecipitate Miz1 protein, and anti-Miz1 antibody did not
co-immunoprecipitate SIRT1 protein (Figure S5B).
We have previously shown that N-Myc protein binds to the
histone deacetylase HDAC1 protein through N-Myc DNA-
binding domain [22]. We next sought to determine which domain
of N-Myc protein directly interacted with SIRT1. Seven different
GST-N-Myc deletion mutant expression constructs were generat-
Figure 2. SIRT1 up-regulates N-Myc protein expression by blocking its degradation. (A, B) BE(2)-C and LAN-1 cells were transfected with
scrambled control (Cont) siRNA, SIRT1 siRNA-1 or SIRT1 siRNA-2 (A), or treated with the SIRT1 inhibitor Cambinol, Tenovin-6 or vehicle control (B),
followed by protein extraction and immunoblot analysis of N-Myc protein. (C) BE(2)-C cells were transfected with scrambled control siRNA, N-Myc
siRNA-1, N-Myc siRNA-2, SIRT1 siRNA-1 or SIRT1 siRNA-2 for 48 hours, followed by treatment with the proteasome inhibitor MG-132 (10 mM) for
3 hours. SIRT1 and N-Myc protein expression was analysed by immunoblot. (D) BE(2)-C cells were transfected with scrambled control siRNA or SIRT1
siRNA-1 for 30 hours, and treated with 50 mM cycloheximide (CHX) for the last 0, 15, 30, 45 or 60 minutes. Protein was extracted from the cells and
subjected to immunoblot analysis of N-Myc. N-Myc protein level was normalized by actin, the ratio of N-Myc protein and actin protein was artificially
set as 1.0 for samples un-treated with CHX, and half life (T1/2) of N-Myc protein was obtained from the line chart.
doi:10.1371/journal.pgen.1002135.g002
Histone Deacetylase SIRT1 Promotes Neuroblastoma
PLoS Genetics | www.plosgenetics.org 5 June 2011 | Volume 7 | Issue 6 | e1002135ed (Figure 5E). GST pull-down assay showed that SIRT1 bound
only the Myc Box I domain (Figure 5F). Taken together, these
findings suggest that SIRT1 forms a transcriptional repressor
complex with N-Myc through binding to its Myc Box 1 domain,
and that the protein complex represses MKP3 gene transcription
by binding to the Sp1-binding sites upstream of MKP3
transcription start site.
SIRT1 was up-regulated and MKP3 down-regulated in
pre-cancerous cells from TH-MYCN transgenic mice
TH-MYCN transgenic mice with the MYCN oncogene in the
germline, driven by the tyrosine hydroxylase (TH) promoter,
develop a tumour phenotype which closely resembles human
neuroblastoma [31]. We have previously shown that 2-week-old
homozygous TH-MYCN transgenic mice develop pre-cancerous
neuroblast cell hyperplasia in celiac and superior cervical ganglia,
which develops into microscopic neuroblastoma in 100% of the
mice by 3 weeks of age [32]. In the current investigations, we
examined whether N-Myc modulated SIRT1 and MKP3 gene
expression in pre-cancerous ganglia cells. As shown in Figure 6A,
SIRT1 mRNA expression was increased by 3-fold, and MKP3
gene expression reduced by approximately 60%, in pre-cancerous
ganglia cells from 2-week-old TH-MYCN transgenic mice,
compared with counterpart normal ganglia cells from 2-week-
old wild type mice. To test whether SIRT1 modulated MKP3
gene expression in the pre-cancerous cells, we extracted and
purified ganglia cells from 2-week-old mice, and treated the cells
with vehicle control or Cambinol for 24 hours. As shown in
Figure 6B, treatment with Cambinol up-regulated MKP3 gene
expression in pre-cancerous ganglia cells from TH-MYCN
transgenic mice, but not in counterpart normal ganglia cells
from wild type mice. These results suggest that N-Myc up-
regulates the expression of SIRT1, N-Myc and SIRT1 repress
MKP3 gene expression, in pre-cancerous cells during tumor
initiation.
Chemo-prevention with the SIRT1 inhibitor Cambinol
suppresses N-Myc–induced neuroblastoma initiation in
vivo
We then examined whether suppression of SIRT1 activity could
partly block tumor initiation in vivo. Five day old homozygous TH-
MYCN transgenic mice were treated with vehicle control or
Cambinol daily for 10 consecutive days (before tumor initiation),
left un-treated for 4 weeks, and sacrificed at the age of 42 days. As
shown in Figure 6C, short-term preventative treatment with
Cambinol before tumor initiation significantly reduced tumor
volume in TH-MYCN transgenic mice four weeks after the
discontinuation of Cambinol treatment. The data confirmed the
major role of SIRT1 in the initiation of N-Myc-induced
neuroblastoma in vivo.
Figure 3. SIRT1 stabilizes N-Myc protein by promoting ERK protein phosphorylation and N-Myc protein phosphorylation at S62. (A,
B) BE(2)-C cells were transfected with scrambled control siRNA, SIRT1 siRNA-1 (left panel) or SIRT1 siRNA-2 (right panel), followed by protein
extraction. (A) Expression of total N-Myc protein, N-Myc protein phosphorylated at S62 (S62-phos) and N-Myc protein phosphorylated at T58 (T58-
phos) was analysed by immunoblot with specific antibodies. (B) Expression of GSK3 protein, total ERK protein and phosphorylated ERK protein (phos-
ERK) was analysed by immunoblot with specific antibodies.
doi:10.1371/journal.pgen.1002135.g003
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N-Myc–induced neuroblastoma progression in vivo
Finally, we examined whether suppression of SIRT1 activity
impaired the progression of established neuroblastoma in vivo.
Four-week-old homozygote N-Myc transgenic mice develop
palpable neuroblastoma in the abdomen with an incidence of
100% [22]. Cohorts of 20 homozygous N-Myc transgenic mice
at the age of 28 days were treated with control or Tenovin-6
daily for 18 days before being euthanized. As shown in
Figure 6D, treatment with Tenovin-6 reduced tumor volume
by approximately 50% (P,0.05) in the N-Myc transgenic mice.
Immunohistochemistry analysis showed significantly increased
expression of MKP3 protein (P,0.001) and decreased expres-
sion of N-Myc protein (P,0.001) (Figure 6E) in tumour tissues
from mice treated with Tenovin-6. These data confirm that
SIRT1 plays a major role in the progression of N-Myc-induced
neuroblastoma in vivo.
Discussion
SIRT1 gene expression and deacetylase activity are repressed in
normal non-malignant cells by tumor suppressors such as p53
[33], hypermethylated in cancer 1 [34] and by the putative tumor
suppressor deleted in breast cancer 1 [35,36]. In this study, we
have shown that N-Myc oncoprotein up-regulates SIRT1 gene
transcription by directly binding to its gene promoter in
neuroblastoma cells, that forced over-expression of N-Myc in
normal cells induces SIRT1 gene expression, and that SIRT1
induces neuroblastoma cell proliferation. Moreover, SIRT1 gene
Figure 4. Repression of MKP3 gene expression is required for SIRT1-induced N-Myc protein stabilization and SIRT1-induced cell
proliferation. (A, C, D) BE(2)-C and LAN-1 cells were transfected with scrambled control (Cont), SIRT1 siRNA or N-Myc siRNA (A, D), or treated with
vehicle control, 55 mM Cambinol or 5 mM Tenovin-6 (C, D). MKP3 mRNA (A, C) and protein (D) expression was analysed by real-time RT-PCR and
immunoblot. (B) B cells from normal mouse bone marrow were transfected with a construct over-expressing full-length N-Myc cDNA or empty vector
(EV). MKP3 gene expression was analysed by real-time RT-PCR. (E) BE(2)-C cells were transfected with scrambled control siRNA, MKP3 siRNA, SIRT1
siRNA, N-Myc siRNA, or a combination of MKP3 siRNA and SIRT1 siRNA. Phosphorylated ERK, total ERK, S62-phosphorylated (S62-phos) N-Myc, T58-
phosphorylated (T58-phos) N-Myc or total N-Myc protein was examined by immunoblot with specific antibodies. (F) BE(2)-C cells were transfected
with scrambled control siRNA, MKP3 siRNA, SIRT1 siRNA, or a combination of MKP3 siRNA and SIRT1 siRNA. In separate experiments, BE(2)-C cells
were transfected with scrambled control or MKP3 siRNA and treated with vehicle control or 55 mM Cambinol for 72 hours. Relative total numbers of
cells were examined by the Alamar blue assay. Error bars represented standard error. *** indicated P,0.001.
doi:10.1371/journal.pgen.1002135.g004
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PLoS Genetics | www.plosgenetics.org 7 June 2011 | Volume 7 | Issue 6 | e1002135Figure 5. SIRT1 and N-Myc repress MKP3 gene transcription by forming a transcriptional repressor complex at MKP3 gene core
promoter. (A) A schematic representation of the MKP3 gene promoter containing the Sp1 binding sites. (B) Dual cross-linking ChIP and quantitative
PCR were applied in BE(2)-C cells. Real-time PCR with primers targeting the negative control region (Amplicon A) or the Sp1-binding sites (Amplicon
B) were performed. Fold enrichment of MKP3 promoter regions immunoprecipitated by pre-immune serum (IgG), anti-Sp1, anti-N-Myc and anti-SIRT1
antibodies was calculated as the logarithm of the difference between the cycle-threshold obtained with pre-immune serum and the cycle-threshold
obtained with the specific antibody. (C) TET-21/N neuroblastoma cells were transfected with a luciferase reporter construct carrying MKP3 gene
promoter region. Luciferase activity of the luciferase reporter construct was determined in the presence (- tetracycline) or absence (+ tetracycline) of
N-Myc expression, normalized to that of renilla, and expressed as relative fluorescence units (RFU). Error bars represented standard error. *** indicated
P,0.001. (D) HEK 293 cells were transfected with constructs expressing empty vector, N-Myc and/or SIRT1. Nuclear protein from the cells was
immunoprecipitated with an anti-N-Myc, anti-SIRT1 or pre-immune serum (IgG) antibody, and co-immunoprecipitation (IP) products were probed
with anti-SIRT1 and anti-N-Myc antibodies by immunoblot. (E) Seven different GST-N-Myc deletion mutant expression constructs were generated.
GST-N-Myc proteins carrying different moieties of the full length N-Myc were obtained. MB represents Myc Box, and bHLH-zip the basic helix-loop-
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transgenic mice, compared with counterpart normal cells from
wild type mice. Taken together, these data suggest that N-Myc
oncoprotein is capable of up-regulating SIRT1 gene expression in
normal, pre-cancerous and cancer cells, that up-regulation of
SIRT1 promotes cell proliferation, and that N-Myc up-regulates
SIRT1 gene expression during malignant transformation in pre-
cancerous cells. It is worth noting that repression of SIRT1 does
not lead to cell death in the neuroblastoma cell lines tested. As the
most common mechanism through which SIRT1 blocks cell death
is deacetylation of p53 protein, we hypothesize that repression of
SIRT1 does not induce significant cell death in BE(2)-C and LAN-
1 cells, because p53 is mutated and N-Myc does not modulate cell
survival/death in the neuroblastoma cells [21,22].
The present study has shown that repression of SIRT1 does not
affect N-Myc mRNA expression, but reduces ERK protein
phosphorylation, N-Myc protein phosphorylation at S62, and
consequently enhances proteasome-mediated N-Myc protein
degradation. Importantly, we have identified MKP3 as one of
the genes most robustly induced by SIRT1 siRNA. We have also
shown that repression of MKP3 gene expression blocks the effects
of SIRT1 siRNA on ERK protein de-phosphorylation, N-Myc
protein de-phosphorylation at S62 and N-Myc protein degrada-
tion. Since phosphorylated ERK stabilizes Myc proteins through
phosphorylating Myc at S62 [4–6] and MKP3 specifically de-
phosphorylates and inactivates ERK protein [26,27], our data
suggests that SIRT1 stabilizes N-Myc protein by repressing the
expression of MKP3, leading to ERK protein phosphorylation and
N-Myc protein phosphorylation at S62. Moreover, our data
showing lower expression of MKP3 in pre-cancerous ganglia cells
from N-Myc transgenic mice further support this notion.
Previously, Otto et al have shown that Aurora A stabilizes N-
Myc protein by interacting with N-Myc and SCF
Fbxw7 ubiquitin
ligase, and therefore counteracting N-Myc protein ubiquitination
and degradation [5]. Our findings reveal a novel pathway through
which N-Myc and SIRT1 form a positive feedback loop which
represses MKP3 gene expression, leading to ERK protein
phosphorylation and consequently N-Myc protein phosphoryal-
tion at S62 and N-Myc protein stabilization.
SIRT1 is known to repress gene transcription by binding to
Sp1-binding sites at target gene promoters [28]. We have
previously shown that N-Myc repress the transcription of the
tissue transglutaminase gene by recruiting HDAC1 protein to N-
Myc DNA-binding domain at gene promoter of tissue transglu-
taminase [22]. Our present study shows that N-Myc and SIRT1
bind to MKP3 gene core promoter at Sp1-binding sites, repress
MKP3 promoter activity and reduce MKP3 gene expression. Our
protein co-immunoprecipitation assay reveals that N-Myc and
SIRT1 form a protein complex, and GST pull-down assay
demonstrates that SIRT1 directly binds to Myc Box 1 domain of
N-Myc protein. These data suggest that N-Myc and SIRT1 are
contemporaneously bound to form a transcriptional repressor
complex at the Sp1-binding sites of MKP3 gene promoter, and
consequently repress MKP3 gene transcription. Our data provide
the first evidence that a Myc oncoprotein can bind to SIRT1
protein through Myc Box 1 domain, that Myc oncoproteins may
possess a more widespread capacity for transcriptional repression
by recruiting SIRT1 protein to target gene promoters, and that
Myc-mediated transcriptional repression could be reversed by
SIRT1 inhibitors.
A number of small molecule inhibitors of class I and II HDACs
are currently in clinical trials for the treatment of malignancies of
various organ origins [37]. The SIRT1 inhibitor Cambinol and
Tenovin-6 have shown promising anti-cancer effects in a range of
cancer cell lines and in animal models of Burkitt’s lymphoma and
skin cancer [23,24]. In this study, we have found that suppression
of SIRT1 with Cambinol or Tenovin-6 re-activates MKP3 gene
expression, reduces N-Myc protein level and induces neuroblas-
toma cell growth arrest. Moreover, Cambinol up-regulates MKP3
gene expression in both neuroblastoma and pre-cancerous cells,
but not in counterpart normal cells, preventative therapy with
Cambinol reduces tumorigenesis in N-Myc transgenic mice, and
therapy with Tenovin-6 reduced tumour progression in neuro-
blastoma-bearing N-Myc transgenic mice in association with
reduced N-Myc protein expression and increased MKP3 protein
expression in tumor tissues. Our data suggest that repression of
SIRT1 with specific inhibitors, such as Cambinol and Tenovin-6,
could be an effective strategy for the prevention and therapy of N-
Myc-induced neuroblastoma, and possibly other Myc-induced
cancers.
There are currently controversies and debates regarding the
role of SIRT1 in cancer. Wang RH et al showed that ectopic
expression of SIRT1 in BRCA1 mutant breast cancer cells inhibits
tumour formation by deacetylating survivin protein [20]. Howev-
er, in the same study, ectopic expression of SIRT1 in BRCA1 wild
type breast cancer cells did not inhibit tumour formation. While
SIRT1 was reported to suppress intestinal tumorigenesis in the
APC
min/+ mouse model by deacetylating and inactivating b-
catenin [19], a recent study revealed that there was no difference
in tumor development when APC
+/min mice crossed with SIRT1-
null mice, and that average polyp size was slightly smaller in
SIRT1-null APC
+/min mice [38]. Moreover, repression of SIRT1
in APC wild type colon cancer cells induced massive apoptosis in a
FOXO4-dependent manner [39]. In the case of prostate cancer,
SIRT1 could promote prostatic intraepithelial neoplasia lesion
formation through repressing androgen responsive gene expres-
sion and consequently inducing autophagy [40]. However, SIRT1
expression is increased in human prostate cancer tissues,
compared with adjacent normal prostate tissues [9,41], and
SIRT1 promotes prostate cancer by deacetylating and inactivating
FOXO1 protein [41] and by protecting cells against oxidative
stress [42]. In addition, SIRT1 is well-known to protect cancer
cells against apoptosis by deacetylating p53 [35,36], Bcl6 [23],
FOXO3a [43] and Ku70 [44] in cancer of various organ origins.
It is therefore likely that SIRT1 can function either as an oncogene
or tumour suppressor, depending on SIRT1 targets in the cellular
context, with the dominant target determining the outcome.
Despite the discrepancies with regard to the functional role of
SIRT1 in cancer, SIRT1 inhibitors have unanimously shown anti-
cancer effects. For example, the SIRT1 inhibitor Melatonin
inhibits prostate cancer progression in transgenic adenocarcinoma
of the mouse prostate (TRAMP) mice [45], Cambinol partly
blocks lymphoma development in nude mice [23], Tenovin-6
suppresses breast cancer and melanoma cell proliferation in vitro
and blocks melanoma progression in nude mice [24], and
Salermide induces dramatic apoptosis in human colon and breast
cancer cells [46].
The current study demonstrates that SIRT1 functions as an
oncoprotein in N-Myc oncogenesis through forming a transcrip-
tional repressor complex with N-Myc, repressing MKP3 gene
helix-zipper region. (F) Immobilized GST-N-Myc proteins were loaded with in vitro translated SIRT1 protein. GST-N-Myc complexes were analyzed by
immunoblot with an anti-SIRT1 antibody. Amount of loaded GST proteins was also determined by immunoblot.
doi:10.1371/journal.pgen.1002135.g005
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PLoS Genetics | www.plosgenetics.org 9 June 2011 | Volume 7 | Issue 6 | e1002135Figure 6. SIRT1 plays an important role in N-Myc–induced neuroblastoma initiation and progression in vivo. (A, B) Celiac and superior
cervical ganglia were dissected from wild type mice and homozygous TH-MYCN transgenic mice at 2 weeks old, and ganglia cells purified. (A) RNA
was extracted from the ganglia cells and subjected to real-time RT-PCR analysis of SIRT1 and MKP3 gene expression. SIRT1 and MKP3 expression in
ganglia cells from normal mice was artificially set as 1.0. (B) The ganglia cells were treated with vehicle control or 55 mM Cambinol for 24 hours,
followed by real-time RT-PCR analysis of MKP3 gene expression. MKP3 gene expression in ganglia cells treated with vehicle control was artificially set
as 1.0. (C) Five day old homozygous TH-MYCN transgenic mice were injected intra-peritoneally with Cambinol at the dose of 100 mg/kg/day (number
=8) or vehicle control (number =8) for 10 consecutive days. They were then left un-treated for 4 weeks, and sacrificed at the age of 42 days. Tumor
volume was measured and analyzed. (D) Forty-eight day old homozygous TH-MYCN transgenic mice were injected intra-peritoneally with Tenovin-6
at the dose of 50 mg/kg/day (number =10) or vehicle control (number =10) for 18 consecutive days. The mice were euthanized at the completion of
therapy. Tumor volume was measured and analysed. (E) Neuroblastoma tissues from the TH-MYCN transgenic mice treated with control or Tenovin-6
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and that SIRT1 inhibitors exert anticancer effects against N-Myc-
induced neuroblastoma in vitro and in vivo. It is unlikely that p53
plays a central role in the effects of SIRT1 in neuroblastoma since
the BE(2)-C and LAN-1 cells used in our study do not express
functional p53 protein due to p53 gene mutation.
In summary, this study demonstrates that a novel pathway,
involving transcriptional up-regulation of SIRT1, repression of
MKP3 and consequent ERK protein phosphorylation, contributes
to N-Myc oncoprotein stability, neuroblastoma cell proliferation
and in vivo tumorigenesis. Moreover, the SIRT1 inhibitors
reactivate MKP3 gene expression in tumor and pre-cancerous
cells, reduce N-Myc protein expression, inhibit N-Myc-induced
tumor initiation and progression in vivo. These findings therefore
identify SIRT1 as an important co-factor for N-Myc oncogenesis,
and provide important evidence for the potential application of
SIRT1 inhibitors in the prevention and therapy of N-Myc-induced
neuroblastoma.
Materials and Methods
Cell culture
Neuroblastoma BE(2)-C, LAN-1, TET-21/N and SHEP TET-
OFF cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 5% fetal calf serum. Mouse bone marrow-
derived B-cells were extracted from mouse bone marrow as
described previously [21], and cultured in RPMI 1640 medium
supplemented with 10% heat-inactivated fetal calf serum, 50 mM
2-mercaptoethanol and 10 ng/ml recombinant mouse interleukin-
7. The animal work was approved by the Animal Care and Ethics
Committee of the University of New South Wales, Sydney,
Australia.
siRNA and plasmid transfection
Cells were transfected with plasmid or siRNA (from Qiagen or
Ambion) using Lipofectamine 2000 reagent [21].
RT-PCR and immunoblot analyses
Gene expression in tumor cells was examined by quantitative
real-time RT-PCR as described previously [22,47]. For the
analysis of protein expression by immunoblot, cells were lysed,
protein extracted and separated by gel electrophoresis. After
western transfer, membranes were probed with mouse anti-N-Myc
antibody (1:1000), rabbit anti-SIRT1 antibody (1:1000), mouse
anti-MKP3 antibody (1:200) (all from Santa Cruz Biotech, CA),
mouse anti-phosphorylated ERK (1:1000), rabbit anti-total ERK
(1:1000) (both from Millipore), mouse anti-total GSK3, rabbit
anti-S62 phosphorylated c-Myc (N-Myc) antibody (Abcam, Cam-
bridge, MA) (1:1000) or rabbit anti-T58 phosphorylated c-Myc (N-
Myc) antibody (Abcam) [48], followed by horseradish peroxidase-
conjugated anti-mouse (1:10000) or anti-rabbit (1:20000) antise-
rum (Santa Cruz Biotech). Protein bands were visualized with
SuperSignal (Pierce, Rockford, IL). The membranes were lastly re-
probed with an anti-actin antibody (Sigma) as loading controls.
Affymetrix gene array study
Neuroblastoma BE(2)-C cells were transfected with scrambled
control siRNA, N-Myc siRNA or SIRT1 siRNA. Thirty hours
after transfection, RNA was extracted from the cells with RNeasy
mini kit. Differential gene expression was examined with
Affymetrix GeneChip Gene 1.0 ST Arrays (Affymetrix), according
to the manufacturer’s instruction. Results from the microarray
hybridization were analysed with GeneSpring software (Gene-
Spring).
Cell proliferation assay
Cell proliferation was examined with Alamar blue assays [49].
Briefly, cells were plated into 96 well plates, transfected with
various siRNAs or treated with different dosages of Cambinol.
Seventy-two hours later, cells were incubated with Alamar blue
(Invitrogen) for 5 hours, and plates were then read on a micro-
plate reader at 570/595 nm. Results were calculated according to
the optical density absorbance units and expressed as percentage
change in cell number.
Dual cross-linking ChIP assay
Dual cross-linking ChIP was performed as we previously
described [22], with 5 mg control IgG, anti-Sp1 and anti-SIRT1
antibodies. MKP3 promoter region was detected with quantitative
PCR with specific primers.
ChIP assay
ChIP assays were performed with an anti-Miz1 antibody or pre-
immune serum (IgG) with samples from BE Miz1-i cells, which
were derived from neuroblastoma BE(2)-C cells after stable
transfection with a ponasterone-inducible Miz1 expression con-
struct [29]. Binding of Miz1 to MKP3 and p21 (positive control)
promoter regions was analysed by quantitative PCR with specific
primers.
Luciferase assay
Modulation of MKP3 gene promoter activity by N-Myc was
analysed by luciferase assays. The MKP3 gene promoter construct
has been described previously [a kind gift from Dr. J. Licht [50]].
TET-21/N neuroblastoma cells were transiently transfected with
the MKP3 gene promoter construct using Lipofectamine 2000
(Invitrogen). Six hours after transfection, medium was replaced
and cells were treated with 1 mg/ml tetracycline for 48 hours
before Luciferase Assay. Firefly and Renilla activity was measured
with a Dual Luciferase Assay kit (Promega, Madison, WI).
Co-immunoprecipitation assay
Human embryonic HEK 293 cells were transiently
transfected with 12 mg of pCMV14-N-Myc, pCDNA3.1-SIRT1
or both with Lipofectamine2000 (Invitrogen) for 36 hours. 0.5 mg
of nuclear protein was then incubated overnight with 2 mg of anti-
N-Myc, anti-SIRT1 or control IgG antibody. Eluted proteins were
immunoblotted with anti-N-Myc or anti-SIRT1 antibody. In
separate experiments, HEK293 cells were transiently
transfected with 12 mg of pCDNA3.1-SIRT1, pCDNA3.1-Miz1
[29] or both with Lipofectamine2000 (Invitrogen) for 36 hours.
0.5 mg of nuclear protein was then incubated overnight with 2 mg
of anti-SIRT1, anti-Miz1 or control IgG antibody. Eluted proteins
were immunoblotted with an anti-SIRT1 or anti-Miz1 antibody
(Santa Cruz Biotech).
were examined by immunohistochemistry with anti-N-Myc or MKP3 antibodies and visualized with DAB. The nucleus was counter-stained with
haematoxylin. N-Myc and MKP3 protein expression was analysed using the scoring system described in Materials and Methods, and expressed as
histology score. Error bars indicated standard error. * indicated P,0.05, and ** P,0.01.
doi:10.1371/journal.pgen.1002135.g006
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Seven different GST-N-Myc deletion mutant expression
constructs were generated as we described previously [22]. GST-
N-Myc proteins were expressed in E.coli, purified and immobi-
lized onto glutathione agarose beads (Sigma). The derived beads
were incubated with in vitro-translated SIRT1 protein (TNT Quick
Coupled Transcription/Translation System, Promega) pre-treated
with DNase (GE Healthcare). Purified complexes were analyzed
by immunoblot, using an anti-SIRT1 antibody (Sigma).
Gene expression studies in N-Myc transgenic mice
We have acquired TH-MYCN transgenic mice from Dr William
Weiss [31], and established a stable colony of the mice [21,22,32].
Two week old homozygous MYCN transgenic mice and matched 2
week old wild type mice from the same hemizygous MYCN
transgenic mothers were sacrificed. After superior cervical and
celiac ganglia were dissected, ganglia cells were purified and
cultured as we have described previously [32]. Briefly, celiac and
superior cervical ganglia were dissected from mice and placed in
Hanks’ balanced salt solution (Invitrogen) containing 1 mg/ml
collagenase (Sigma) at 4uC for 30 minutes and then dissociated by
adding 0.05% trypsin at 37uC for 5 minutes. After washed twice,
the samples were re-suspended and triturated in Neurobasal-A
media (Invitrogen) supplemented with 0.5 mM L-glutamine,
25 mM glutamic acid and B27 (Invitrogen; 2% vol/vol). Ganglia
cells were then cultured in complete Neurobasal-A media on poly-
D-lysine and laminin-coated coverslips in 24-well plates and
treated with vehicle control or 55 mM Cambinol for 24 hours,
followed by RNA extraction and RT-PCR analysis of gene
expression. All animal work was approved by the Animal Care
and Ethics Committee of the University of New South Wales.
Chemoprevention of neuroblastoma in N-Myc transgenic
mice
Five days old MYCN transgenic mice were randomised into two
groups, and injected intraperitoneally with Cambinol at the dosage
of 100 mg/kg/day or vehicle control once a day for 10
consecutive days. The treatment was then dis-continued for 4
weeks, mice sacrificed at the age of 42 days, and tumor volume
measured with a caliph as we described previously [22].
Experimental therapy of neuroblastoma in TH-MYCN
transgenic mice
Four-week-old homozygous TH-MYCN transgenic mice develop
spontaneous abdominal neuroblastoma with an incidence of
100%. Twenty-eight day old TH-MYCN transgenic mice were
randomised into two groups, and injected intra-peritoneally with
Tenovin-6 at the dosage of 50 mg/kg/day or vehicle control [24]
once a day for 18 consecutive days. At the completion of the
therapy, the mice were euthanized, tumors collected, tumor
volume measured with a caliph as we described previously [22],
and tumor tissues paraffin-embedded.
Immunohistochemistry studies
Mouse tissue sections were de-paraffinised, rehydrated, blocked
with 3% hydrogen peroxide and serum. Mouse anti-N-Myc
antibody (1:200) and mouse anti-MKP3 antibody (1:100) were
biotinylated with an Animal Research Kit (DakoCytomation,
Glostrup, Denmark), according to the manufacturer’s instructions.
Tumour sections were incubated with the biotinylated mouse anti-
N-Myc antibody or mouse anti-MKP3 antibody and then
streptavidin-horseradish peroxidase, and visualized with diamino-
benzidine (DAB) solution (DakoCytomation). The cell nucleus was
counterstained with haematoxylin. Analyses of the immunohisto-
chemistry staining were performed using our previously estab-
lished scoring system [51]. Briefly, high level of expression of N-
Myc and MKP3 was defined as positive staining with intensity 3+
in .33% of cells; moderate-high staining was defined as intensity
2+ in .33% of positive staining, up to intensity 3+ in 33% of cells;
and low expression was defined as any staining with 1+ intensity,
up to intensity 2+ in 33% of cells.
Statistical analysis
All experiments were repeated for at least 3 times in duplicates.
All data for statistical analysis were calculated as mean 6 standard
error. Differences were analyzed for significance using ANOVA
among groups or unpaired t-test for two groups. A probability
value of 0.05 or less was considered significant.
Supporting Information
Figure S1 N-Myc is over-expressed in normal mouse bone
marrow-derived B cells after transfection with a construct
encoding full-length N-Myc cDNA. Mouse bone marrow-derived
B cells were purified from normal mouse bone marrow and
transfected with a construct encoding full-length N-Myc cDNA or
empty vector (EV) for 48 hours. N-Myc expression in the cells was
analysed by real-time RT-PCR. N-Myc expression in cells
transfected with EV was artificially set as 1.0.
(PDF)
Figure S2 Repression of SIRT1 does not consistently decrease
N-Myc gene expression. (A) Neuroblastoma BE(2)-C and LAN-1
cells were transfected with scrambled control siRNA, SIRT1
siRNA-1 or SIRT1 siRNA-2 for 48 hours. (B) BE(2)-C and LAN-1
cells were treated with vehicle control, 55 mM Cambinol or 5 mM
Tenovin-6 for 48 hours. Gene expression of N-Myc was analysed
by real-time RT-PCR. N-Myc gene expression in control siRNA-
transfected samples (A) or vehicle control-treated samples (B) was
artificially set as 1.0.
(PDF)
Figure S3 Repression of MKP3 contributes to SIRT1-induced
cell proliferation. (A) LAN-1 cells were transfected with scrambled
control siRNA, MKP3 siRNA, SIRT1 siRNA, or combination of
MKP3 siRNA and SIRT1 siRNA. (B) LAN-1 cells were
transfected with scrambled control or MKP3 siRNA and treated
with vehicle control or Cambinol for 72 hours. (A, B) Relative
total numbers of cells were examined by the Alamar blue assay,
measured as optical density (OD) units of absorbance, and
expressed as a percentage change of absorbance for the
experimental samples, over that for control samples transfected
with scrambled control siRNA (A) or treated with vehicle (B).
Error bars represented standard error. *** indicated P,0.001.
(PDF)
Figure S4 SIRT1 siRNA and the SIRT1 inhibitor Cambinol
reactivate the expression of the same set of genes. Neuroblastoma
BE(2)-C and LAN-1 cells were transfected with scrambled control
siRNA or SIRT1 siRNA-1, or treated with Cambinol at the
concentration of 100 mM, 55 mM (IC50 for inhibiting SIRT1) or
0 mM (vehicle control) for 48 hours. Gene expression of EGR1 (A),
KCNIP4 (B) and PLCB1 (C) was analysed by real-time RT-PCR.
Gene expression in control siRNA-transfected samples or vehicle
control-treated samples was artificially set as 1.0. Error bars
represented standard error. * indicated P,0.05, ** P,0.01 and
*** P,0.001.
(PDF)
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MKP3. (A) BE Miz1-i cells, which were derived from neuroblas-
toma BE(2)-C cells after stable transfection with a ponasterone-
inducible Miz1 expression construct, were used. ChIP assays were
performed in BE Miz1-i cells with or without ponasterone
treatment to determine the association of Miz1 to MKP3 gene
promoter and p21 gene promoter (positive control). Region A
represented the promoter region distal from the transcription start
site, and region B the promoter region surrounding the
transcription start site. Relative enrichment of a given promoter
region obtained with a specific antibody was compared with that
obtained with pre-immune serum (IgG), which was set to 1 in the
graph. Results are the mean 6 standard error of 4 independent
experiments. (B) HEK 293 cells were transfected with constructs
expressing empty vector, SIRT1 and/or Miz1. Nuclear protein
from the cells was immunoprecipitated with an anti-SIRT1, anti-
Miz1 or pre-immune serum (IgG) antibody, and co-immunopre-
cipitation (IP) products were probed with anti-SIRT1 and anti-
Miz1 antibodies by immunoblot.
(PDF)
Dataset S1 Genes up-regulated by SIRT1 siRNA-1 by more
than 2 fold, as identified by Affymetrix gene array analysis, in
neuroblastoma BE(2)-C cells 30 hours after transfection with
SIRT1 siRNA-1 or control siRNA.
(XLS)
Dataset S2 Genes down-regulated by SIRT1 siRNA-1 by more
than 2 fold, as identified by Affymetrix gene array analysis, in
neuroblastoma BE(2)-C cells 30 hours after transfection with
SIRT1 siRNA-1 or control siRNA.
(XLS)
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